Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension

A method for treating glaucoma or ocular hypertension in a subject's eye which comprises contacting the surface of the eye with an effective intraocular pressure reducing amount of a therapeutically active and physiologically acceptable derivative of prostaglandin PGA, PGB, PGD, PGE or PGF in which the omega chain has the formula:

• 21
• wherein
• C is a carbon atom (the number is indicated within parenthesis)
• B is a single bond, a double bond or a triple bond
• D is a chain with 1-10 carbon atoms, optionally interrupted by hetero atoms O, S, or N, the substituents on each carbon atom being H, alkyl groups, preferably lower alkyl groups with 1-5 carbon atoms, a carbonyl group, or a hydroxyl group
• R2 is a ring structure such as a phenyl group which is unsubstituted or has at least one substituent selected from C1-C5 alkyl groups, C1-C4 alkoxy groups, trifluoromethyl groups, C1-C3 aliphatic acylamino groups, nitro groups, halogen atoms, and phenyl group;
• or an aromatic heterocyclic group having 5-6 ring atoms, like thiazol, imidazole, pyrrolidine, thiopene and oxazole;
• or a cycloalkane or a cycloalkene with 3-7 carbon atoms in the ring, optionally substituted with lower alkyl groups with 1-5 carbon atoms,

An ophthalmological composition for topical treatment of glaucoma or ocular hypertension which comprises an effective intraocular pressure reducing amount of a therapeutically active and physiologically acceptable prostaglandin derivative of PGA, PGB, PGD, PGE or PGF in which the omega chain has the formula:

• 22
• wherein
• C is a carbon atom (the number is indicated within parenthesis)
• B is a single bond, a double bond or a triple bond
• D is a chain with 1-10 carbon atoms, optionally interrupted by hetero atoms O, S, or N, the substituents on each carbon atom being H, alkyl groups, preferably lower alkyl groups with 1-5 carbon atoms, a carbonyl group, or a hydroxyl group
• R2 is a ring structure such as a phenyl group which is unsubstituted or has at least one substituent selected from C1-C5 alkyl groups, C1-C4 alkoxy groups trifluoromethyl groups, C1-C3 aliphatic acylamino groups, nitro groups, halogen atoms, and phenyl group;
• or an aromatic heterocyclic group having 5-6 ring atoms, like thiazol, imidazole, pyrrolidine, thiopene and oxazole;
• or a cycloalkane or a cycloalkene with 3-7 carbon atoms in the ring, optionally substituted with lower alkyl groups with 1-5 carbon atoms,
• in an ophthalmologically compatible carrier.